Author

Saba Sile

Teprotumumab for the Treatment of Active Thyroid Eye Disease

2020 · Raymond S. Douglas, George J. Kahaly, et al. · New England Journal of Medicine · 757

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials

2021 · George J Kahaly, Raymond S Douglas, et al. · The Lancet Diabetes & Endocrinology · 199

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

2021 · Raymond S. Douglas, George J. Kahaly, et al. · Ophthalmology · 178

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

2014 · Nicola Longo, Cary O Harding, et al. · The Lancet · 167

Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema

2007 · James Brian Byrd, Karine Touzin, et al. · Hypertension · 147

PDF

Utility of clinical pathway and prospective case management to achieve cost and hospital stay reduction for aortic aneurysm surgery at a tertiary care hospital

1997 · Satish C. Muluk, Lisa Painter, et al. · Journal of Vascular Surgery · 53

PDF

A likelihood ratio test of population Hardy‐Weinberg equilibrium for case‐control studies

2008 · Chang Yu, Sanguo Zhang, et al. · Genetic Epidemiology · 38

CLCNKB-T481S and essential hypertension in a Ghanaian population

2009 · Saba Sile, Digna R Velez, et al. · Journal of Hypertension · 36

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease

2021 · Yan Xin, Fengyan Xu, et al. · Clinical Pharmacokinetics · 29

PDF

Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis

2001 · Saba Sile, Barry M. Wall · American Journal of Kidney Diseases · 20

Molecular physiology of renal ClC chloride channels/transporters

2006 · Saba Sile, Carlos G Vanoye, et al. · Current Opinion in Nephrology & Hypertension · 17

Functional BSND Variants in Essential Hypertension *

2007 · Saba Sile, Niloufar B. Gillani, et al. · American Journal of Hypertension · 15

Haplotype Diversity in Four Genes (CLCNKA, CLCNKB, BSND, NEDD4L) Involved in Renal Salt Reabsorption

2007 · Saba Sile, Digna R. Velez, et al. · Human Heredity · 15

PDF

Cysteamine bitartrate delayed‐release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open‐label study of treatment‐naïve patients <6 years of age with nephropathic cystinosis

2021 · Maria Helena Vaisbich, Juliana Caires Ferreira, et al. · JIMD Reports · 9

Congenital long QT syndrome aggravated by salt-wasting nephropathy

2005 · Dawood Darbar, Saba Sile, et al. · Heart Rhythm · 9

Teprotumumab for the treatment of active thyroid eye disease

2020 · Douglas RS, Kahaly GJ, et al. · Yearbook of pediatric endocrinology · 8

Tetrahydrobiopterin (6R-BH4): Novel Therapy for Endothelial Dysfunction in Sickle Cell Disease

2008 · Lewis Hsu, Kenneth I Ataga, et al. · Blood · 5

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data

2022 · Terry J Smith, Rajib K Bhattacharya, et al. · Journal of the Endocrine Society · 3

PDF

Teprotumumab use in a real-world setting: Expanded access program findings

2021 · Raymond S. Douglas, Yao Wang, et al. · Investigative Ophthalmology & Visual Science · 2

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)

2020 · Yan Xin, Fengyan Xu, et al. · Journal of the Endocrine Society · 2

PDF

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups

2020 · George J Kahaly, Terry J Smith, et al. · Journal of the Endocrine Society · 2

PDF

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States

2020 · Marius N Stan, Robert Holt, et al. · Journal of the Endocrine Society · 1

PDF

Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Commentary

2008 · Eric Grouzmann, Thierry Buclin, et al. · Hypertension · 1

Divergent neurocognitive outcomes in mucopolysaccharidosis (MPS) type IIIB siblings: Tralesinidase alfa versus supportive management

2026 · Irene J. Chang, Jacqueline Madden, et al. · Molecular Genetics and Metabolism

Long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT) results in profound and durable reduction of heparan sulfate (HS) and stabilization of cognitive function and cortical gray matter volume (CGMV) in patients with Sanfilippo syndrome type B (MPS IIIB)

2026 · Nicole M. Muschol, Mona Lindschau, et al. · Molecular Genetics and Metabolism

Works count: 32

Citation count: 1,713

H-index: 13

I10-index: 13